2nd International conference on Heart Cardiovascular Diseases

Sep 19-20, 2022

|

Vancouver, Canada



About Conference


Heart & Cardiovascular Diseases 2022 regards each one of the individuals to go to the "2nd International conference on Heart & Cardiovascular Diseases" amidst September 19-20, 2022 at Vancouver, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops, Speaker sessions.

Theme: Use Heart to Connect and Harness the power of digital health to improve awareness

The goal of the Heart & Cardiovascular Diseases 2022 is to give a transformative professional evolution experience that covers the entire scale of current research in Cardiology and the application of new technologies for the treatment of heart failure or cardiovascular diseases.

Heart & Cardiovascular Diseases 2022 will join world-class professors, scientists, researchers, students, Perfusionists, cardiologists to discuss methodology for ailment remediation for heart diseases, Electrocardiography, Heart Failure, Pediatric Cardiology and health disorders. We have planned to give various information that will keep specialists helpful with the issues impacting the expectations, finding and treatment of cardiovascular diseases.

This conference includes well-known and knowledgeable speakers, covering both broad and specific topics of interest. Main aims of our conference is to provide cardiac physicians, specialists, nurses, technologists and anyone professionally involved in Cardiovascular Disease and Molecular Cardiology with an opportunity to learn about the convolution of the disease, discuss interventional procedures, get a knowledge of new and advanced cardiac practices and their efficiency and efficacy in the treatment of various cases, and understand local realities and practical constraints in improving patient-care.

LexisConferences Conferences deals with a meetings of 1000+ Global Events thorough of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe and Asia with sponsorship from 1000 more sensible social requests and disseminates 700+ Open get to journals which contains more than 30000 unmistakable personalities, reputed specialists as article board people.

Target Audience


  • Associations and Societies of Cardiology
  • Business Entrepreneurs
  • Cardiac Oncology & Pharmacology
  • Cardiac Surgeons
  • Cardiologists
  • Cardiology and Cardiac Nursing Associations
  • Cardiology Imaging
  • Cardiology Students, Scientists
  • Cardio-thoracic Surgeons
  • CEO’s of Organizations
  • Clinical EP & Internal Medicine
  • Directors
  • Echocardiography
  • Emergency Medicine
  • Endocrinology
  • General Cardiology
  • Health care Industries
  • Hypertension & Pharmacy
  • Interventional Cardiology
  • Manufacturing Medical Devices Companies
  • Medicine Experts
  • Paediatric & Preventive Cardiology
  • Paediatric Cardiologists
  • Paediatric Care Centres
  • Professors, Associate Professors
  • Research Institutes
  • Research Scholars
  • Researcher
  • Vascular Biologists

Participation Options and Benefits


We provide the participants with different modes or ways to participate as Delegate or Speaker under either ACADEMIC / STUDENT / BUSINESS Category. The mode of participation is webinar through PowerPoint Presentation/ Video Presentation.

  • Keynote speaker: 45-50 minutes
  • Speaker (oral presentation): 25-30 minutes (only one person can present)
  • Speaker (workshop): 45-50 minutes (more than 1 can present)
  • Speaker (special session): 45-50 minutes (more than 1 can present)
  • Speaker (symposium): more than 45 minutes (more than 1 can present)
  • Delegate(only registration): will have access to all the sessions with all the benefits of registration
  • Poster presenter:  can present a poster and enjoy the benefits of delegateRemote attendance:  can participate via video presentation or e-poster presentation
  • Exhibitor: can exhibit his/her company’s products by booking exhibitor booths of different sizes

 PARTICIPATION BENEFITS:


  • Attend Keynote Presentation by world’s most eminent researchers
  • Access to all the sessions
  • Get OCM certificate
  • Get worldwide acknowledgment to your profile and Research
  • Get your abstracts published with unique DOI in International Journals
  • Get up to 50% discounts for publishing your entire article in our open access International Journals
  • Get Handbooks and conference kits
  • Get an access to the network with eminent personalities from worldwide

Supporting Journals: **All the selected Abstracts/ papers presented will be published in the Supporting Journals below:

•        Journal Name: Journal of Clinical & Experimental Cardiology

•        Journal Name:  Journal of Cardiovascular Diseases & Diagnosis

•        Journal Name: International Journal of Cardiovascular Research

Join our team Heart & Cardiovascular Diseases 2022 in this beautiful city of the Canada and let us make this professional gathering a Great success

Market Analysis


Aim of this 2nd International conference on Heart & Cardiovascular Diseases is to ensure clinically appropriate cost effective care for your members with heart disease. It arises mainly because of ischemic heart disease, stroke, dyslipidemia, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease, hypertension and others. The main cause for this disorder includes unhealthy dietary habits, obesity, smoking, high cholesterol, lack of physical activity, excessive alcohol and poor lifestyle. Cardiovascular Diseases is accountable for approximately 15 million deaths each year across the globe and it also states that it is a major cause of death in adults approx. to 50%. A committed forum for the increasing, execution and exchange of information about Cardiovascular Medicine and its areas can be brought up by National/International symposiums, Organizing Conferences and Workshops.

Aetiology, clinical characteristics and therapy:

The aetiology of Heart Failure was hypertension in 45% of the patients while cardiomyopathies were behind 28%, rheumatic heart disease 12%, Ischemic heart disease 9% and other reasons (probable tuberculosis or HIV-related cardiomyopathies, endomyocardial fibrosis and obstructive lung disease) in 6%. is Among those with cardiomyopathies, Heart Failure due to idiopathic dilated cardiomyopathy was most frequent (81%), followed by postpartum cardiomyopathy (15%) while hypertrophic and restrictive cardiomyopathies were rare (5%). Rheumatic mitral disease with regurgitation was the most prevalent valvular lesion (81%), followed by mitral stenosis (15%) and aortic regurgitation (3%).

Importance and Scope: -

Heart & Cardiovascular Diseases 2022 will be the best platform for all the scientists, cardiologists, oncologists, electro physiologists, surgeons, nurses, research scholars, students who are working in this field to exchange their knowledge related to Cardiology and Cardiac Surgery. This international event is an effort to find an alternative for invasive imaging technique against heart diseases and heart failure conditions in adults & children.

Growth of Cardiology Market: -

North America is the dominant regional market for heart diagnostics with a share of approximately 47% of the overall heart diagnostics market in terms of revenue in 2018, followed by Europe which accounted for around 38% share in the market and then by Asia accounting for 15% share.

Statistics of Physicians, Researchers and Academicians working on Cardiology Research

The main part of the world associated with Cardiology field are Directors, Heads, Deans, Professors, Scientists, Researchers, Doctors, Students and Writers of Pediatric Cardiology Department as well as Founders and Employees of the related companies, Associations members, related organizations, laboratories members etc.

The important goal of heart-failure therapy is to inhibit the progression of congestive heart failure through pharmacological, device-based therapies. Therefore, there have been efforts to develop device-based therapies aimed at improving cardiac reserve and optimizing pump function to meet metabolic requirements. The course of congestive heart failure is often worsened by other conditions, including new-onset arrhythmias, ischemia and infarction, valvulopathy, decompensation, end-organ damage, and therapeutic refractoriness, that have an impact on outcomes. The onset of such conditions is sometimes heralded by subtle pathophysiologic changes, and the timely identification of these changes may promote the use of preventive measures. Consequently, device-based methods could in the future have an important role in the timely identification of the subtle pathophysiologic changes associated with congestive heart failure. 

Related Companies/Industries:

  • MEDNAX, Inc
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • Roche
  • Bristol-Myers Squibb
  • United Therapeutics
  • Astellas
  • Actelion
  • Sanofi
  • Takeda
  • Otsuka
  • Gilead Sciences
  • Johnson & Johnson

Related Associations and Societies:

Related Universities:

  • University Maastricht/Academic Hospital Maastricht
  • Medical University of Graz
  • University of Debrecen Medical School
  • University of Nicosia Medical School
  • Imperial College London
  • Johns Hopkins University
  • Bukovinian State Medical University
  • Heidelberg University
  • Hamburg University
  • University of Lodz
  • Yale University
  • North-western University
  • Vanderbilt University
  • University of Rochester